Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nasal desmopressin vs cyproheptadine for negative symptoms in schizophrenia
IRCT20160523028008N33Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Feb 2025
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3 trial of desmopressin and cyproheptadine in schizophrenia (2 arms), sponsored by Hamadan University of Medical Sciences. Primary endpoint: Change in negative symptoms of schizophrenia. Started Feb 2025; status: completed.
02
Drugs
desmopressincyproheptadine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on IRCT20160523028008N33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20160523028008N33.